Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC
Public ClinicalTrials.gov record NCT03674827. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES AND TREATMENT INTENSIFICATION OF A VACCINE-BASED IMMUNOTHERAPY REGIMEN-2 (VBIR-2) (PF-06936308) FOR ADVANCED NON-SMALL CELL LUNG CANCER AND METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Part 1of the study will evaluate the safety, pharmacokinetics, pharmacodynamics and immunogenicity of increasing doses of a vaccine-based immunotherapy regimen (VBIR-2) for patients with advanced or metastatic non-small cell lung cancer and metastatic triple-negative breast cancer. Part 2 will evaluate the safety, pharmacokinetics and pharmacodynamics, immunogenicity and preliminary evidence of efficacy of the Expansion dose of VBIR-2 in participants with advanced or metastatic non-small cell lung cancer.
Study identification
- NCT ID
- NCT03674827
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 36 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 27, 2018 (Actual)
- Primary completion
- Sep 27, 2021 (Actual)
- Completion
- Sep 27, 2021 (Actual)
- Last update posted
- Aug 23, 2024
2018 – 2021
United States locations
- U.S. sites
- 34
- U.S. states
- 10
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCSD Medical Center - Encinitas | Encinitas | California | 92024 | — |
| UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Hospital) | La Jolla | California | 92037 | — |
| UC San Diego Perlman Medical Offices | La Jolla | California | 92037 | — |
| UC San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| Ronald Reagan UCLA Medical Center | Los Angeles | California | 90095 | — |
| UCLA Hematology/Oncology | Los Angeles | California | 90095 | — |
| UC San Diego Medical Center - Hillcrest | San Diego | California | 92103 | — |
| UCLA Hematology/Oncology - Parkside | Santa Monica | California | 90404 | — |
| UCLA Hematology/Oncology - Santa Monica | Santa Monica | California | 90404 | — |
| UCSD Medical Center - Vista | Vista | California | 92081 | — |
| H Lee Moffitt Cancer Center & Research Institute Inc | Tampa | Florida | 33612 | — |
| The University of Chicago Medical Center, CCD - Investigational Drug Service Pharmacy | Chicago | Illinois | 60637 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| University of Chicago Comprehensive Cancer Center at Silver Cross Hospital | New Lenox | Illinois | 60451 | — |
| Orland Park - University of Chicago Center for Advanced Care | Orland Park | Illinois | 60462 | — |
| Horizon Oncology Research, LLC | Lafayette | Indiana | 47905 | — |
| InnerVision Advanced Medical Imaging | Lafayette | Indiana | 47905 | — |
| The University of Kansas Cancer Center, Investigational Drug Services | Fairway | Kansas | 66205 | — |
| The University of Kansas Clinical Research Center | Fairway | Kansas | 66205 | — |
| The University of Kansas Cancer Center | Westwood | Kansas | 66205 | — |
| Norton Cancer Institute Downtown | Louisville | Kentucky | 40202 | — |
| Norton Cancer Institute Pharmacy, Downtown Pharmacy | Louisville | Kentucky | 40202 | — |
| Norton Hospital | Louisville | Kentucky | 40202 | — |
| Siteman Cancer Center - St. Peters | City of Saint Peters | Missouri | 63376 | — |
| Siteman Cancer Center - West County | Creve Coeur | Missouri | 63141 | — |
| Barnes-Jewish Hospital | St Louis | Missouri | 63110 | — |
| Washington University Infusion Center Pharmacy | St Louis | Missouri | 63110 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Siteman Cancer Center - South County | St Louis | Missouri | 63129 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | — |
| The Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| University of Utah, Huntsman Cancer Hospital | Salt Lake City | Utah | 84112 | — |
| University of Utah, Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| University of Washington Medical Center - Translational Research Unit (TRU) | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03674827, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 23, 2024 · Synced Nov 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03674827 live on ClinicalTrials.gov.